{"schema_version":"secwatch.filing_event.v1","accession":"0001821586-23-000004","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2023-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.792650+00:00","generated_at":"2026-06-17T23:08:46.869635+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moonlake reports FY2022 net loss $64.5M; HS trial top-line expected June 2023","bullets":["Net loss for year ended Dec 31, 2022 was $64.5M vs $53.6M for prior period (March 2021 to Dec 2021).","Cash, equivalents and short-term marketable debt securities $72.1M at Dec 31, 2022; runway into 2H 2024.","Phase 2 HS trial top-line results expected around end of June 2023; final readout by Q4 2023.","Phase 2 PsA trial enrollment on schedule; top-line results anticipated at end of 2023.","Capital Markets Day set for April 19, 2023 in New York and via webcast."],"urls":{"canonical":"https://secwatch.observer/filing/0001821586-23-000004","json":"https://secwatch.observer/filing/0001821586-23-000004.json","markdown":"https://secwatch.observer/filing/0001821586-23-000004.md","text":"https://secwatch.observer/filing/0001821586-23-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/0001821586-23-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/mnlk-20230320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T23:08:46.869635+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f8ff98983834a7f3e0a5d2d23d1f305da958f0c8","claim":"MoonLake Immunotherapeutics reported the fourth quarter and year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $64.5 million.","evidence_excerpt":"MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1821586/000182158623000004/0001821586-23-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the year ended December 31, 2022 was $64.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}